InsuletMEX:PODD 80 Days Payable is 44.07 as of Mar. 2026, which is 26% above its 10-year median of 34.98. GuruFocus rates MEX:PODD with a GF Score™ of 80/100 and a GF Value™ of MXN6,378.07 (Significantly Undervalued). Among 795 Medical Devices & Instruments companies, Insulet ranks worse than 78.11% on this metric.
Insulet's average Accounts Payable for the
three
months ended in Mar. 2026 was MXN2,026 Mil. Insulet's Cost of Goods Sold for the
three
months ended in Mar. 2026 was MXN4,194 Mil.
Hence, Insulet's Days Payable for the
three
months ended in Mar. 2026 was 44.07.
The historical rank and industry rank for Insulet's Days Payable or its related term are showing as below:
MEX:PODD'
s Days Payable Range Over the Past 10 Years
Min: 11.37 Med: 34.98 Max: 61.53
Current: 37.04
During the past 13 years, Insulet's highest Days Payable was 61.53. The lowest was 11.37. And the median was 34.98.
MEX:PODD's Days Payable is ranked worse than 78.11% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs MEX:PODD: 37.04
Insulet's Days Payable
increased
from Mar. 2025 (22.18) to Mar. 2026 (44.07).
It may suggest that Insuletdelayed paying its suppliers.
Insulet Days Payable Related Terms
Insulet Days Payable Historical Data
* Premium members only.
The historical data trend for Insulet's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:PODD vs GMED, PEN, BRKR: Days Payable Comparison
For the Medical Devices subindustry, Insulet's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Insulet Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Days Payable distribution charts can be found below:
* The bar in red indicates where Insulet's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Insulet's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insulet (MEX:PODD) has a Days Payable of 44.07 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Insulet and its competitors. This is 26% above median its historical median of 34.98. Over the past decade, Insulet's Days Payable has ranged from 11.37 to 61.53. According to the industry distribution chart, Insulet ranks #621 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 78.1%.
Is Insulet's Days Payable too high?
Insulet's current Days Payable of 44.07 is 26% above median its 10-year median of 34.98. Over the past 10 years, this metric has ranged from a low of 11.37 to a high of 61.53. The Medical Devices & Instruments industry median Days Payable is 68.07. Insulet's value of 44.07 is 35.3% below this industry median. Based on the distribution chart, Insulet ranks #621 out of 795 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Insulet has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's Days Payable compare to GMED and PEN?
According to the Medical Devices & Instruments industry distribution chart, Insulet ranks #621 out of 795 companies for Days Payable. This places Insulet in the lower half of its industry. The industry median Days Payable is 68.07. Insulet's value of 44.07 is 35.3% below this benchmark. Historically, Insulet's own Days Payable has ranged from 11.37 to 61.53 over the past decade. While the company's 10-year median is 34.98 vs. the industry median of 68.07, Insulet has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Insulet's current Days Payable of 44.07 is 35.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Insulet and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insulet's current Days Payable is 44.07, which is 26% above median its own 10-year median of 34.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (MEX:PODD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN6,378.07, compared to a current price of MXN2,548.13 — trading 60% below its estimated fair value. The current Days Payable is 44.07, which is 26% above median its 10-year median of 34.98 and 35.3% below the Medical Devices & Instruments industry median of 68.07. Insulet's overall GF Score™ is 80/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Insulet (MEX:PODD), the current Days Payable is 44.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insulet (MEX:PODD) Overvalued in 2026?
Based on GuruFocus' analysis, Insulet stock appears to be undervalued.
The current stock price of MXN2,548.13 is trading 60% below its estimated GF Value™ of MXN6,378.07.
GuruFocus considers Insulet to be Significantly Undervalued.
Key valuation signals for MEX:PODD:
Days Payable: 44.07 (26% above median its 10-year median of 34.98)
GF Value™: MXN6,378.07 vs. price of MXN2,548.13 (60% below fair value)
Industry Position: 35.3% below the Medical Devices & Instruments median (#621 of 795)
No single metric tells the full story. See the MEX:PODD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
80GF Score
Get the complete analysis for MEX:PODD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PODD has been successfully added to your 
